Your browser doesn't support javascript.
loading
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden, Sarah P; Rizzuto, Ivana; Suppiah, Puvan; O'Shea, Daniel; Patel, Markand; Spiers, Laura; Sukumaran, Ajithkumar; Bharwani, Nishat; Rockall, Andrea; Gabra, Hani; El-Bahrawy, Mona; Wasan, Harpreet; Leonard, Robert; Habib, Nagy; Ghazaly, Essam.
Afiliación
  • Blagden SP; Department of Surgery and Cancer, Hammersmith Campus, Imperial College, London, W12 0HS, UK. sarah.blagden@oncology.ox.ac.uk.
  • Rizzuto I; Early Phase Clinical Trials Unit, Department of Oncology, Churchill Hospital, Headington, Oxford, OX3 7LE, UK. sarah.blagden@oncology.ox.ac.uk.
  • Suppiah P; Department of Surgery and Cancer, Hammersmith Campus, Imperial College, London, W12 0HS, UK.
  • O'Shea D; NIHR/Wellcome Trust Imperial CRF, Imperial Centre for Translational and Experimental Medicine, Hammersmith Hospital, London, W12 0HS, UK.
  • Patel M; NIHR/Wellcome Trust Imperial CRF, Imperial Centre for Translational and Experimental Medicine, Hammersmith Hospital, London, W12 0HS, UK.
  • Spiers L; NIHR/Wellcome Trust Imperial CRF, Imperial Centre for Translational and Experimental Medicine, Hammersmith Hospital, London, W12 0HS, UK.
  • Sukumaran A; Department of Surgery and Cancer, Hammersmith Campus, Imperial College, London, W12 0HS, UK.
  • Bharwani N; Early Phase Clinical Trials Unit, Department of Oncology, Churchill Hospital, Headington, Oxford, OX3 7LE, UK.
  • Rockall A; Department of Surgery and Cancer, Hammersmith Campus, Imperial College, London, W12 0HS, UK.
  • Gabra H; Department of Surgery and Cancer, Hammersmith Campus, Imperial College, London, W12 0HS, UK.
  • El-Bahrawy M; Department of Radiology, Imperial College Healthcare NHS Trust, London, W12 0HS, UK.
  • Wasan H; Department of Radiology, Imperial College Healthcare NHS Trust, London, W12 0HS, UK.
  • Leonard R; Department of Surgery and Cancer, Hammersmith Campus, Imperial College, London, W12 0HS, UK.
  • Habib N; Clinical Discovery Unit, Early Clinical Development, AstraZeneca, Cambridge, UK.
  • Ghazaly E; Imperial College London, London, W12 0HS, UK.
Br J Cancer ; 119(7): 815-822, 2018 10.
Article en En | MEDLINE | ID: mdl-30206366
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Citidina Monofosfato / Neoplasias / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Citidina Monofosfato / Neoplasias / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido